A carregar...
Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, importa...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Limited
2016-01-01
|
| Colecção: | Journal of Diabetes Research |
| Acesso em linha: | http://dx.doi.org/10.1155/2016/8352957 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|